Is Target a Dividend King?
Popular retail giant Target Corporation (NYSE:TGT) has been in a…
Sell
39
BMRA Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
9.97%
Day range:
$0.32 - $0.35
52-week range:
$0.24 - $1.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.98x
P/B ratio:
1.01x
Volume:
188.1K
Avg. volume:
1.7M
1-year change:
-65.75%
Market cap:
$5.4M
Revenue:
$5.4M
EPS (TTM):
-$0.37
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Biomerica has 3948.58% upside to fair value with a price target of -- per share.
BMRA vs. S&P 500
-
Over the past 5 trading days, Biomerica has underperformed the S&P 500 by -4.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biomerica does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biomerica has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Biomerica reported revenues of $1.8M.
Earnings Growth
-
Biomerica has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Biomerica reported earnings per share of -$0.08.
Enterprise value:
2.6M
EV / Invested capital:
--
Price / LTM sales:
0.98x
EV / EBIT:
--
EV / Revenue:
0.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.51x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$485K
Return On Assets:
-58.67%
Net Income Margin (TTM):
-111.89%
Return On Equity:
-77.23%
Return On Invested Capital:
-77.23%
Operating Margin:
-75.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2023-08-31 | 2024-08-31 | |
| Income Statement | ||||||
| Revenue | $19.2M | $5.4M | $5.5M | $1.7M | $1.8M | |
| Gross Profit | $3M | $913K | $485K | $412K | $289K | |
| Operating Income | -$5.1M | -$6.4M | -$6.5M | -$1.2M | -$1.4M | |
| EBITDA | -$4.5M | -$6M | -$6.1M | -$1.1M | -$1.3M | |
| Diluted EPS | -$0.40 | -$0.41 | -$0.37 | -$0.07 | -$0.08 | |
| Period Ending | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.1M | $8.9M | $9.2M | $11.6M | $6.4M | |
| Total Assets | $15.9M | $11.5M | $11.1M | $13.2M | $7.9M | |
| Current Liabilities | $1.8M | $1.5M | $1.8M | $1.7M | $2.2M | |
| Total Liabilities | $3.3M | $2.7M | $2.7M | $2.5M | $2.5M | |
| Total Equity | $12.6M | $8.8M | $8.3M | $10.8M | $5.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2023-08-31 | 2024-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.1M | -$5.6M | -$5M | -$1.7M | -$1.3M | |
| Cash From Investing | -$126.5K | -$107K | -$52K | -$63K | -- | |
| Cash From Financing | $3.4M | -- | -- | -- | -- | |
| Free Cash Flow | -$2.3M | -$5.7M | -$5M | -$1.7M | -$1.3M | |
BMRA
Sector
Market Cap
$5.4M
$46.7M
Price % of 52-Week High
23.79%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-65.75%
-33.88%
Beta (5-Year)
-1.042
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.33
200-day SMA
Sell
Level
$0.44
Bollinger Bands (100)
Sell
Level
0.29 - 0.39
Chaikin Money Flow
Sell
Level
-78.9M
20-day SMA
Buy
Level
$0.31
Relative Strength Index (RSI14)
Sell
Level
49.62
ADX Line
Buy
Level
27.33
Williams %R
Neutral
Level
-59.5632
50-day SMA
Sell
Level
$0.33
MACD (12, 26)
Buy
Level
0.00
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
289.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.0593)
Sell
CA Score
(Annual)
Level (-1.4562)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.5823)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Stock Forecast FAQ
In the current month, BMRA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BMRA average analyst price target in the past 3 months is --.
-
Where Will Biomerica Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biomerica share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Biomerica?
Analysts are divided on their view about Biomerica share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biomerica is a Sell and believe this share price will drop from its current level to --.
-
What Is Biomerica's Price Target?
The price target for Biomerica over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BMRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biomerica is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BMRA?
You can purchase shares of Biomerica via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biomerica shares.
-
What Is The Biomerica Share Price Today?
Biomerica was last trading at $0.33 per share. This represents the most recent stock quote for Biomerica. Yesterday, Biomerica closed at $0.32 per share.
-
How To Buy Biomerica Stock Online?
In order to purchase Biomerica stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
72
DJT alert for Jan 14
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
